Literature DB >> 31793696

Mitochondrial pharmacology: featured mechanisms and approaches for therapy translation.

Xin Wang1, Gina Galli1, Michelangelo Campanella2,3.   

Abstract

LINKED ARTICLES: This article is part of a themed section on Mitochondrial Pharmacology: Featured Mechanisms and Approaches for Therapy Translation. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.22/issuetoc.
© 2019 The British Pharmacological Society.

Year:  2019        PMID： 31793696      PMCID： PMC6887662          DOI： 10.1111/bph.14820

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN： 0007-1188            Impact factor:   8.739


  10 in total

Review 1.  Exploring mitochondrial cholesterol signalling for therapeutic intervention in neurological conditions.

Authors:  Radha Desai; Michelangelo Campanella
Journal:  Br J Pharmacol       Date:  2019-08-09       Impact factor: 8.739

Review 2.  Xeroderma pigmentosum: overview of pharmacology and novel therapeutic strategies for neurological symptoms.

Authors:  Rosella Abeti; Anna Zeitlberger; Colm Peelo; Hiva Fassihi; Robert P E Sarkany; Alan R Lehmann; Paola Giunti
Journal:  Br J Pharmacol       Date:  2019-01-23       Impact factor: 8.739

3.  Nicotinic ACh receptor α7 inhibits PDGF-induced migration of vascular smooth muscle cells by activating mitochondrial deacetylase sirtuin 3.

Authors:  Dong-Jie Li; Jie Tong; Fei-Yan Zeng; Mengqi Guo; Yong-Hua Li; Hongbo Wang; Pei Wang
Journal:  Br J Pharmacol       Date:  2018-11-04       Impact factor: 8.739

Review 4.  OSCP subunit of mitochondrial ATP synthase: role in regulation of enzyme function and of its transition to a pore.

Authors:  Valentina Giorgio; Federico Fogolari; Giovanna Lippe; Paolo Bernardi
Journal:  Br J Pharmacol       Date:  2018-11-28       Impact factor: 8.739

5.  Mitochondrial depolarization stimulates vascular repair-relevant functions of CD34+ cells via reactive oxygen species-induced nitric oxide generation.

Authors:  Shrinidh Joshi; Yagna P R Jarajapu
Journal:  Br J Pharmacol       Date:  2018-12-09       Impact factor: 8.739

6.  ABT-199 (Venetoclax), a BH3-mimetic Bcl-2 inhibitor, does not cause Ca2+ -signalling dysregulation or toxicity in pancreatic acinar cells.

Authors:  Monika A Jakubowska; Martijn Kerkhofs; Claudio Martines; Dimitar G Efremov; Julia V Gerasimenko; Oleg V Gerasimenko; Ole H Petersen; Geert Bultynck; Tim Vervliet; Pawel E Ferdek
Journal:  Br J Pharmacol       Date:  2018-11-08       Impact factor: 8.739

7.  Inhibiting nucleolin reduces inflammation induced by mitochondrial DNA in cardiomyocytes exposed to hypoxia and reoxygenation.

Authors:  Lars Henrik Mariero; May-Kristin Torp; Christina Mathisen Heiestad; Anton Baysa; Yuchuan Li; Guro Valen; Jarle Vaage; Kåre-Olav Stensløkken
Journal:  Br J Pharmacol       Date:  2019-10-27       Impact factor: 8.739

Review 8.  Mitochondrial function in the heart: the insight into mechanisms and therapeutic potentials.

Authors:  Binh Yen Nguyen; Andrea Ruiz-Velasco; Thuy Bui; Lucy Collins; Xin Wang; Wei Liu
Journal:  Br J Pharmacol       Date:  2018-08-02       Impact factor: 8.739

Review 9.  Three-dimensional electron microscopy techniques for unravelling mitochondrial dysfunction in heart failure and identification of new pharmacological targets.

Authors:  Hussam M Daghistani; Bodour S Rajab; Ashraf Kitmitto
Journal:  Br J Pharmacol       Date:  2018-10-25       Impact factor: 8.739

Review 10.  Programmed necrosis in cardiomyocytes: mitochondria, death receptors and beyond.

Authors:  Junxia Zhang; Dairu Liu; Mao Zhang; Yan Zhang
Journal:  Br J Pharmacol       Date:  2018-06-25       Impact factor: 8.739
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.